Literature DB >> 18267124

CSN5 binds to misfolded CFTR and promotes its degradation.

Gaëlle Tanguy1, Loïc Drévillon, Nicole Arous, Afia Hasnain, Alexandre Hinzpeter, Janine Fritsch, Michel Goossens, Pascale Fanen.   

Abstract

Cystic fibrosis is mainly caused by mutations that interfere with the biosynthetic folding of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The aim of this study was to find cellular proteins interacting with CFTR and regulating its processing. We have used a genetic screen in yeast to identify such proteins and identified CSN5 that interacted with the third cytoplasmic loop of CFTR. CSN5 is the 5th component of the COP9 signalosome, a complex of eight subunits that shares significant homologies to the lid subcomplex of the 26S proteasome and controls the stability of many proteins. The present study shows that CSN5 associates with the core-glycosylated form of CFTR and suggests that this association targets misfolded CFTR to the degradative pathway. Identifying CSN5 as a new component of the degradative pathway is an important step towards the goal of unraveling the sorting between misfolded and correctly folded CFTR proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18267124     DOI: 10.1016/j.bbamcr.2008.01.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Geminiviruses subvert ubiquitination by altering CSN-mediated derubylation of SCF E3 ligase complexes and inhibit jasmonate signaling in Arabidopsis thaliana.

Authors:  Rosa Lozano-Durán; Tabata Rosas-Díaz; Giuliana Gusmaroli; Ana P Luna; Ludivine Taconnat; Xing Wang Deng; Eduardo R Bejarano
Journal:  Plant Cell       Date:  2011-03-25       Impact factor: 11.277

2.  COP9 signalosome complex subunit 5, an IFT20 binding partner, is essential to maintain male germ cell survival and acrosome biogenesis†.

Authors:  Qian Huang; Hong Liu; Jing Zeng; Wei Li; Shiyang Zhang; Ling Zhang; Shizhen Song; Ting Zhou; Miriam Sutovsky; Peter Sutovsky; Ruggero Pardi; Rex A Hess; Zhibing Zhang
Journal:  Biol Reprod       Date:  2020-02-12       Impact factor: 4.285

3.  COP9 signalosome subunit Csn8 is involved in maintaining proper duration of the G1 phase.

Authors:  Cheng Liu; Li-Quan Guo; Suchithra Menon; Dan Jin; Elah Pick; Xuejun Wang; Xing Wang Deng; Ning Wei
Journal:  J Biol Chem       Date:  2013-05-20       Impact factor: 5.157

4.  Alternative splicing at a NAGNAG acceptor site as a novel phenotype modifier.

Authors:  Alexandre Hinzpeter; Abdel Aissat; Elvira Sondo; Catherine Costa; Nicole Arous; Christine Gameiro; Natacha Martin; Agathe Tarze; Laurence Weiss; Alix de Becdelièvre; Bruno Costes; Michel Goossens; Luis J Galietta; Emmanuelle Girodon; Pascale Fanen
Journal:  PLoS Genet       Date:  2010-10-07       Impact factor: 5.917

5.  COMMD1-mediated ubiquitination regulates CFTR trafficking.

Authors:  Loïc Drévillon; Gaëlle Tanguy; Alexandre Hinzpeter; Nicole Arous; Alix de Becdelièvre; Abdel Aissat; Agathe Tarze; Michel Goossens; Pascale Fanen
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

6.  Mycobacterium tuberculosis alters the metalloprotease activity of the COP9 signalosome.

Authors:  Lia Danelishvili; Lmar Babrak; Sasha J Rose; Jamie Everman; Luiz E Bermudez
Journal:  mBio       Date:  2014-08-19       Impact factor: 7.867

7.  Analysis of the role of COP9 Signalosome (CSN) subunits in K562; the first link between CSN and autophagy.

Authors:  Claire Pearce; Rachel E Hayden; Christopher M Bunce; Farhat L Khanim
Journal:  BMC Cell Biol       Date:  2009-04-28       Impact factor: 4.241

8.  Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain.

Authors:  Norbert Odolczyk; Janine Fritsch; Caroline Norez; Nathalie Servel; Melanie Faria da Cunha; Sara Bitam; Anna Kupniewska; Ludovic Wiszniewski; Julien Colas; Krzysztof Tarnowski; Danielle Tondelier; Ariel Roldan; Emilie L Saussereau; Patricia Melin-Heschel; Grzegorz Wieczorek; Gergely L Lukacs; Michal Dadlez; Grazyna Faure; Harald Herrmann; Mario Ollero; Frédéric Becq; Piotr Zielenkiewicz; Aleksander Edelman
Journal:  EMBO Mol Med       Date:  2013-08-27       Impact factor: 12.137

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.